No Prescription |
 |
 | ||
|
Bactroban Ointment Generic Mupirocin |
|
| ||
No Prescription » Prescription Drugs 2 » Bactroban Ointment Generic Mupirocin BACTROBAN ointment contains mupirocin (2% w/w) as the active ingredient.Mupirocin is an antibiotic. Antibiotics work by killing bacteria which can cause infection. BACTROBAN ointment is used for the treatment of certain types of skin infections such as school sores (impetigo) infection of the hair root and boils. BACTROBAN is also used when infection occurs in skin damaged by eczema dermatitis psoriasis herpes (cold sores) wounds cuts grazes insect bites minor burns etc. BACTROBAN ointment is for use on your skin only. Buy Bactroban Ointment Generic Mupirocin and other Prescription Drugs 2 products online at Medstore. Buy Online at Medstore - Click Here!
About Bactroban Ointment Generic Mupirocin: Product Type: Prescription Drugs 2 Bactroban Ointment ( Generic Mupirocin ) Bactroban Ointment (Generic Mupirocin) Generic Mupirocin 2%w/w 15gm 45gm(3 x 15gm) Generic Mupirocin Bactroban Ointment
View more Prescription Drugs 2 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
